Prospective Study of White Blood Cells
Sponsor
Quell Therapeutics Limited (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04838171
Collaborator
(none)
10
1
44.3
0.2
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
10 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
Actual Study Start Date
:
Mar 24, 2021
Anticipated Primary Completion Date
:
Dec 1, 2024
Anticipated Study Completion Date
:
Dec 1, 2024
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Specimen collection to support development of engineering Treg
|
Other: White blood cell and blood collection
Mononucleocytes will be collected via apheresis
|
Outcome Measures
Primary Outcome Measures
- WBC characterisation to support the development of engineered regulatory T cells. [5 years]
number, type and function of white blood cells in healthy controls and in patients
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Quell Investigator Site 01 | London | United Kingdom |
Sponsors and Collaborators
- Quell Therapeutics Limited
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Quell Therapeutics Limited
ClinicalTrials.gov Identifier:
NCT04838171
Other Study ID Numbers:
- QEL-RP-001
First Posted:
Apr 8, 2021
Last Update Posted:
Apr 8, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: